Parameter
| Biomarker | RAGE | Full name | Receptor for Advanced Glycation End-products | Molecular Type | Protein |
|---|---|---|---|---|---|
| Molecular Formula | / | Molecular Weight | / | Core Functional Dimensions | Diagnosis, prognosis, therapeutic targets |
| Disease | PCa | Disease Subtypes | / | ||
| Organ | Prostate | Test Sample / Technology Platform | Tumor tissue (IHC, WB) imaging (targeting RAGE multimodal nanoprobes) | ||
| Pathobiological Mechanisms | RAGE, a cell surface receptor, binds to various ligands (e.g., AGEs, HMGB1, and S100 proteins), activating the PI3K/Akt/NF-κB signaling pathway. This activation drives chronic inflammation, thereby promoting tumor growth, invasion, and treatment resistance. | ||||
| Clinical Availability Status | Research verification | ||||
| Notes and Dynamics | RAGE possesses multifaceted potential in diagnosis, prognosis assessment, and therapeutic targeting. Current research is advancing the clinical validation of RAGE diagnostics and the clinical translation of targeted imaging technologies. | ||||